Breaking the Crosstalk of the Cellular Tumorigenic Network by Low-Dose Combination Therapy in Lung Cancer Patient-Derived Xenografts

Selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft tumors were treated with a low dose combination of cabozantinib, afatinib, plerixafor and etoricoxib.